Original Investigation
Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry

https://doi.org/10.1016/j.jacc.2015.10.060Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

Despite advances in hospital management in recent years, it is not clear whether mortality after acute pulmonary embolism (PE) has decreased over time.

Objectives

This study describes the trends in the management and outcomes of acute symptomatic PE.

Methods

We identified adults with acute PE enrolled in the registry between 2001 and 2013. We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies. Using multivariable regression, we examined temporal trends in risk-adjusted rates of all-cause and PE-related death to 30 days after diagnosis.

Results

Among 23,858 patients with PE, mean length of stay decreased from 13.6 to 9.3 days over time (32% relative reduction, p < 0.001). For initial treatment, use of low-molecular-weight heparin increased from 77% to 84%, whereas the use of unfractionated heparin decreased from 22% to 8.4% (p < 0.001 for trend for all comparisons). Thrombolytic therapy use increased from 0.7% to 1.0% (p = 0.07 for trend) and surgical embolectomy use doubled from 0.3% to 0.6% (p < 0.01 for trend). Risk-adjusted rates of all-cause mortality decreased from 6.6% in the first period (2001 to 2005) to 4.9% in the last period (2010 to 2013) (p = 0.02 for trend). Rates of PE-related mortality decreased over time, with a risk-adjusted rate of 3.3% in 2001 to 2005 and 1.8% in 2010 to 2013 (p < 0.01 for trend).

Conclusions

In a large international registry of patients with PE, improvements in length of stay and changes in the initial treatment were accompanied by a reduction in short-term all-cause and PE-specific mortality.

Key Words

heparin
length of stay
outcomes
prognosis
surgical embolectomy
survival
thrombolysis

Abbreviations and Acronyms

CT
computed tomography
PE
pulmonary embolism
sPESI
simplified Pulmonary Embolism Severity Index
V/Q
ventilation/perfusion
VTE
venous thromboembolism

Cited by (0)

The RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) Registry was supported by Sanofi Spain (through an unrestricted educational grant) and Bayer Pharma AG. Bayer Pharma AG’s support was limited to the part of the RIETE Registry outside of Spain, which accounts for 22.21% of the total patients included. Dr. Jiménez has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; has served as a speaker or a member of a speakers bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, ROVI, and Sanofi; and has received grants for clinical research from Sanofi and ROVI. Dr. Guijarro has served as an advisor or consultant for Bayer Health Care Pharmaceuticals, Boehringer Ingelheim, and Bristol-Myers Squibb; and has served as a speaker or a member of a speakers bureau for Bayer Health Care Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, and Sanofi. Dr. Otero has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Leo Pharma, Pfizer, ROVI, and Sanofi; has served as a speaker for Bayer HealthCare Pharmaceuticals, Leo Pharma, ROVI, and Sanofi; and has received grants for clinical research from Leo Pharma and ROVI. Dr. Meyer has received grants and nonfinancial support from Boehringer Ingelheim, Leo Pharma, and Bayer HealthCare; has received travel support from Leo Pharma, Bayer, and Daiichi-Sankyo; has performed uncompensated lectures for Bristol-Myers Squibb-Pfizer, Bayer, Leo Pharma, Daiichi-Sankyo, and Boehringer-Ingelheim; and is an uncompensated board member for Leo Pharma, Bayer, Bristol-Myers Squibb-Pfizer, and Daiichi-Sankyo. Dr. Yusen has received research funding from Bayer HealthCare Pharmaceuticals, Inc., Portola, Inc., Pfizer, Inc. and Bristol-Myers Squibb in the past 3 years; and has served as a consultant for Bayer HealthCare, Inc., Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Johnson & Johnson, Ortho Pharmaceuticals, Inc., Organon, Inc., Pfizer, Inc., Portola, Inc., Sanofi, and SCIOS, Inc. in the past 3 years. Dr. Monreal has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Leo Pharma, Pfizer, and Sanofi; has served as a speaker or a member of a speakers bureau for Bayer HealthCare Pharmaceuticals, Daiichi-Sankyo, Leo Pharma, and Sanofi; and has received grants for clinical research from Sanofi and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Jiménez and de Miguel-Díez contributed equally to this work.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.